✦ LIBER ✦

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

✍ Scribed by WESTHOVENS, R.; KREMER, J. M.; MORELAND, L. W.; EMERY, P.; RUSSELL, A. S.; LI, T.; ARANDA, R.; BECKER, J.-C.; QI, K.; DOUGADOS, M.

Book ID: 127205321
Publisher: Journal of Rheumatology Publishing Company
Year: 2009
Tongue: English
Weight: 245 KB
Volume: 36
Category: Article
ISSN: 0315-162X
DOI: 10.3899/jrheum.080813

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of the selective costimulation mo

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

✍ M. Weinblatt; B. Combe; A. Covucci; R. Aranda; J. C. Becker; E. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

Immunogenicity, Safety, and Efficacy of

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study

✍ Nash, Peter ;Nayiager, Sauithree ;Genovese, Mark C. ;Kivitz, Alan J. ;Oelke, Kur 📂 Article 📅 2013 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 249 KB

The efficacy and safety of rituximab in

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

A phase IIb dose-ranging study of the or

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

✍ Joel M. Kremer; Stanley Cohen; Bethanie E. Wilkinson; Carol A. Connell; Jonathan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB

The selective estrogen receptor α agonis

The selective estrogen receptor α agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: A phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine

✍ Ronald F. van Vollenhoven; Jos G. A. Houbiers; Frank Buttgereit; Joanna in 't Ho 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 1 views

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB